Altaris Capital Partners to acquire Perrigo Rx business for $1.5bn
(adsbygoogle = window.adsbygoogle || []).push({}); Altaris Capital Partners has agreed to acquire the prescription pharma (Rx) business of Perrigo Company plc, an Ireland-based pharma company, for More...
Roivant Sciences to acquire Silicon Therapeutics to boost drug discovery capabilities
Roivant Sciences has agreed to acquire Silicon Therapeutics, a Boston-based drug design, research, and development company, for $450 million, in an all-share deal. The Swiss biopharma company will also make additional More...
Merck to acquire US biotech company Pandion Therapeutics for $1.8bn
Merck has agreed to acquire Pandion Therapeutics, a Massachusetts-based clinical-stage biotech company, for about $1.85 billion in an all-cash deal. Pandion Therapeutics is engaged in developing therapeutics for More...
Eurofins Scientific to acquire Beacon Discovery to expand drug discovery capabilities
Eurofins Scientific, a testing laboratories company based in Luxembourg, has agreed to acquire Beacon Discovery, a drug discovery and contract research organization (CRO), engaged in the research of G-Protein Coupled More...
Human tissue developer Humacyte to go public via $1.1bn merger with Alpha Healthcare
Humacyte, a clinical-stage biotech platform company, has agreed to merge with blank check company Alpha Healthcare Acquisition Corp. (AHAC), in a deal that values the combined firm at $1.1 billion. Based in Durham, More...
Sandoz to acquire GSK’s cephalosporin antibiotics business in $500m worth deal
Sandoz, a division of Swiss pharma giant Novartis, has agreed to acquire GSK’s cephalosporin antibiotics business in a deal worth up to $500 million. The deal gives Sandoz global rights to the Zinnat, Zinacef, More...
Jazz Pharmaceuticals to acquire Epidiolex developer GW Pharmaceuticals for $7.2bn
Irish biopharma company Jazz Pharmaceuticals has agreed to acquire British pharma company GW Pharmaceuticals in a cash-cum-stock deal worth $7.2 billion. Upon closing of the deal, the combined firm is expected to More...
Horizon Therapeutics to acquire Viela Bio for $3bn to grow rare disease portfolio
Horizon Therapeutics, an Irish biopharma company, has agreed to acquire Viela Bio, a US-based biotech company, for $53 per share in cash or about $3.05 billion in a move to significantly expand its development pipeline More...
Nordic Capital offers to acquire Advanz Pharma for $846m
Nordic Capital has made an offer to acquire Advanz Pharma, a UK-based specialty pharma company, for about $846 million in cash. Advanz Pharma is said to focus strategically on complex medicines in Europe. The company’s More...
Thermo Fisher acquires Henogen viral vector manufacturing business in Belgium from Novasep
Thermo Fisher Scientific has completed the acquisition of Groupe Novasep’s acquisition of viral vector manufacturing business in Belgium – Henogen for nearly €725 million in cash. The divested viral vector More...